Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

Market Cap	1.05T +6.6%
Revenue (ttm)	335.93B +3.2%
Net Income	42.85B -24.2%
EPS	51.42 -24.1%
Shares Out	n/a
PE Ratio	24.58
Forward PE	23.94
Dividend	8.00 (0.63%)
Ex-Dividend Date	Jul 10, 2025

Volume	1,592,833
Average Volume	3,261,414
Open	1,265.30
Previous Close	1,265.30
Day's Range	1,255.00 - 1,307.70
52-Week Range	1,148.40 - 1,379.70
Beta	0.29
RSI	54.03
Earnings Date	May 12, 2026

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 27,811
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: DRREDDY

Financial Performance

In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.